Sutro Biopharma’s CTO, Dr. Shabbir Anik, has contributed to 15 INDs and 10 NDAs, making him a great choice to sit down with for a chat with Business Of Biotech about the mechanics of GMP and chemistry, manufacturing, and controls (CMC) strategies in emerging biopharma enterprises. Listen now and subscribe so you never miss an episode.
CEO Tim Walbert talks about how his company, Horizon Therapeutics, has gone from acquiring commercial drugs and remarketing them to using their R&D to focus more on bio-based medicines such as monoclonal antibodies and genetically engineered proteins.
How Dr. Nancy Chang turned an embattled company in financial freefall and on the heels of clinical failure into a leading clinical-stage biopharma—and how the disruption of a global pandemic made Ansun Biopharma a formidable contender in the treatment of COVID-19.
It’s all happening at CNS Summit 2020: Don’t miss exclusive interviews, COVID-19 vaccine tracking, curated networking, monthly social events and performances, and interactive exhibits. CNS Summit is the premiere community for life sciences leaders who are not afraid to challenge the status quo. Join now for year-round programming and our four-day Summit, October 29 to November 1.